DN 1924
Alternative Names: Dantôn; DN-1924Latest Information Update: 31 Mar 2008
At a glance
- Originator Dendreon Corporation
- Class Antibodies; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hodgkin's disease; Leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 12 Apr 2006 This compound is still in active development
- 25 Oct 2000 Preclinical development for Hodgkin's disease in USA (Parenteral)
- 25 Oct 2000 Preclinical development for Leukaemia in USA (Parenteral)